Full Press Release Details
Phase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months.
BIIB
Phase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
Key Takeaway: Phase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis